Predictive Tools in Preclinical Development and Compound Selection

Minimising front-loading risk in pre-and early clinical development to reduce downstream attrition ,Monday 26th and Tuesday 27th April 2004,Kempinski Hotel Bristol, Berlin

Despite intensive ongoing investment in technologies to support preclinical research, the attrition rate in drug discovery continues to be a real problem for the pharma industry. This conference will be examining how tools for preclinical development are being developed and implemented today, focusing specifically on predictive modeling and compound selection. The impressive group of experts working in the field of predictive tools and modeling, include speakers from: Pfizer Global R&D, AstraZeneca, NV Organon, Novartis Pharma AG, Aventis Pharma AG, F. Hoffmann-La Roche, Schering AG, and many other key industry players.
View the agenda and register online at: http://www.ef-international.co.uk/preclinical/pr
For further information please contact:,James Stackhouse on Tel: [phone],Or email: [e-mail],http://www.ef-international.co.uk/preclinical/pr

Kraje

United Kingdom